| |
|
| |
| News |
| |
| Aug 29, 2010: Tata Capital Ltd. invested in Novalead for development of Galnobax and further development of Novalead pipeline. |
| |
| March 23, 2010: Novalead filed IND for Galnobax at USFDA. |
| |
| Dec 2009: Novalead completes development of Galnobax formulation. |
| |
| May 2008: Novalead initiates development of stable formulation for Galnobax. |
| |
| Oct 30, 2007: NovaLead announces preclinical results for GALNOBAX - a small molecule diabetic wound drug. Expects clinical trial preparation to start in first half 2008. |
| |
| Oct 30, 2007: VLife Board announces de-merger of its research division into a new company NovaLead Pharma Pvt. Ltd. The new company to proceed with new round of funding for clinical development of its pipeline. |
| |
| Events |
| |
| Novalead participated in Euro-QSAR held during September 22-26 2010. Dr. Subhash Ajmani presented novel multi-targeted QSAR approach for lead optimization developed by Novalead. |
|
|
| |
 |
|
|
|
NovaLead Pharma discovers and develops small molecule therapeutic agents capable of multiple mechanism of action for unmet needs and areas needing improved therapeutics.
The candidate pipeline of NovaLead has a balanced mix of new chemical entities and new indications for FDA approved drugs with an addressable market estimated at over US$ 15 billion.
With majority of indications qualifying for fast-track approval from the FDA, NovaLead candidates are expected to reach market in a span of next 2 years to 7 years subject to satisfactory clinical validation. |
|
|
